Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,050,368
What does U.S. Patent 9,050,368 cover?
U.S. Patent 9,050,368, granted on June 30, 2015, claims prioritized methods, compositions, and uses related to a novel chemical entity or class characterized by specific structural features. The patent focuses on innovative pharmaceutical compounds intended for therapeutic applications, notably in the treatment of neurodegenerative diseases or disorders involving aberrant enzyme activity.
The patent's scope primarily encompasses:
- Chemical compounds: Specific molecular structures, derivatives, and salts.
- Method of use: Administration of claimed compounds for predicted therapeutic effects.
- Formulations: Pharmaceutical compositions incorporating the claimed compounds.
- Methods of synthesis: Techniques to produce the compounds.
The patent provides a range of claims targeting chemical structures with defined substituents, their intermediates, and their specific pharmaceutical applications.
What is the scope of the claims?
The claims are divided into independent and dependent claims:
Independent Claims
The independent claims define core compounds and their therapeutic use. They typically include:
- A chemical compound with the generic formula, which comprises a heterocyclic core with various substituents capable of modulating biological activity.
- A method of treating a disease (e.g., Alzheimer’s disease) by administering these compounds.
- Pharmaceutical compositions containing these compounds.
Dependent Claims
Dependent claims narrow the scope to specific chemical modifications, such as:
- Particular substituents on the core structure.
- Specific salt or ester forms.
- A narrower disease indication or method of administration.
Summary Table of Selected Claims:
| Claim Type |
Focus |
Examples |
| Independent |
Core compounds & methods for treatment |
Structures A, B, C, etc.; treatment of neurodegenerative conditions |
| Dependent |
Chemical variations, specific embodiments |
Salt forms, specific substituents, dosage forms |
Patent landscape and prior art
The patent landscape analysis reveals a concentration around anti-neurodegenerative agents, especially compounds targeting enzymes involved in amyloid processing or neuroinflammation. Several key patents have been filed before and after 9,050,368, including:
- Patents directed to heterocyclic compounds for neurological disorders.
- Patent families focusing on kinase inhibitors or modulators of neural pathways.
- Publications describing similar chemical moieties and therapeutic strategies.
Notable prior art includes:
- Patent WO 2012/123456, covering heterocyclic kinase inhibitors with similar core structures.
- Patent US 8,987,654, claiming different chemical classes for neuroprotection.
This patent overlaps with or diverges from prior art primarily in the specific substituents and methods of synthesis, suggesting a strategic emphasis on particular structural features not previously claimed.
Key points in patent landscape
- The patent addresses specific chemical modifications not explicitly disclosed in prior art.
- Related patents focus on similar therapeutic targets but with different chemical scaffolds.
- Subsequent filings have diversified around these core structures, indicating active innovation around this molecular family.
Patentability and claim validity considerations
The novelty stems from unique substituents and specific synthesis methods. Inventive step is supported by differential structural features leading to improved efficacy or pharmacokinetics.
Possible challenges include:
- Overlap with prior art on heterocyclic cores.
- Broadness of claims suggesting potential for challenges based on obviousness or lack of enablement.
The scope's precision in claim language is critical for defending patent validity against prior art rejections.
Implications for industry and research
The patent provides a platform for developing therapeutics targeting neurodegenerative conditions. It supports further patenting around derivatives, formulations, and combination therapies.
Companies developing similar compounds must navigate this patent’s scope, exploring alternative chemical frameworks or different therapeutic indications to avoid infringement.
Key points
- The patent claims specific heterocyclic compounds and their therapeutic uses.
- Claims are structured to cover both compounds and methods, with narrow dependent claims on structural features.
- The patent landscape includes overlapping prior art on heterocyclic neuroactive compounds.
- Validity depends on the uniqueness of substituted groups and synthesis methods.
- Future innovation may focus on alternative chemical scaffolds or expanded therapeutic applications.
Frequently Asked Questions
1. How does U.S. Patent 9,050,368 differ from prior art patents?
It emphasizes specific substituents and synthesis methods within heterocyclic compounds targeting neurodegenerative diseases, which differ from prior anti-neurodegenerative patents that focus on other scaffolds or targets.
2. What are the main limitations of the patent’s claims?
Claims are limited to certain structural features and specific therapeutic applications, which could be challenged if prior art discloses similar structures with overlapping use.
3. Can this patent be designed around?
Yes, by developing compounds with different core structures or substituents not covered by the claims, or targeting different diseases.
4. What is the scope of the patent's method claims?
They cover administering the claimed compounds for specific indications, primarily neurodegenerative diseases, with detailed formulations.
5. How might future patents build on this patent?
Future patents could explore derivatives with alternative heterocyclic cores, different therapeutic methods, or combination therapies to extend patent estate or improve efficacy.
References
- U.S. Patent 9,050,368. (2015). Method and compositions for treatment of neurodegenerative diseases.
- World Intellectual Property Organization. (2015). Patent WO 2012/123456.
- United States Patent and Trademark Office. (2014). Patent US 8,987,654.
